Aspire Biopharma Holdings, Inc. to acquire FireFish TopCo, LLC

Aspire Biopharma Holdings, Inc. has agreed to acquire FireFish TopCo, LLC, a healthcare sector entity based in the United States. The strategic acquisition was formally announced on 12 June 2026, marking a significant consolidation within the US biopharmaceutical landscape. The transaction structure involves the purchase of the target company by the acquiring firm, with the consideration type specified as cash. This arrangement allows Aspire Biopharma to integrate FireFish TopCo’s assets and operations into its existing portfolio, thereby expanding its capabilities in the healthcare market. The deal reflects a direct acquisition strategy rather than a merger of equals or a management-led buyout, positioning the buyer to leverage the target’s specialized focus.

The transaction was completed on 6 August 2026, following the announcement period. Both the buyer and the target are headquartered in the United States, facilitating a domestic integration process. The specific financial value of the deal was not disclosed to the public, and no currency was reported in the available records. As a result, the economic scale of the acquisition remains undisclosed, though the completion date confirms the successful closure of the agreement. The transaction is now final and the assets have been transferred.